Merck Gruppe

Merck reported Q2 revenue growth but recorded a net loss due to a one-time R&D charge from the acquisition of Terns. Together with Moderna, Merck released positive phase-3 results for a personalized mRNA therapy in resected melanoma that significantly delayed recurrence and distant metastases. The data pushed the stock to a record high and could open long-term new growth opportunities for Keytruda combinations and a new therapy platform. » Más en finanzen.net

Merck's stock rose about 3.4% in the morning to $154.03 and reached a new 52-week high of $154.49. The catalyst was the phase-3 data from the INTerpath-001 trial of Intismeran Autogen, a personalized mRNA vaccine against melanoma, which met the primary endpoint of recurrence-free survival and a key secondary endpoint of distant-metastasis-free survival in high-risk patients. The combination of Intismeran with Keytruda showed significantly better efficacy than Keytruda alone. Several analysts therefore raised their ratings and price targets markedly, strengthening the revaluation of Merck's growth prospects ahead of Keytruda's expected patent expiry in 2028. » Más en de.investing.com

A collaboration between Merck and Moderna shows that combining Keytruda with Moderna’s skin cancer vaccine prevents recurrences of melanoma in many patients and reduces metastasis. The study reports no additional serious side effects compared with Keytruda alone. Analysts see strong sales potential; approval could come in 2027 and bring annual revenues of several billion dollars by 2035. The success does not change Keytruda’s impending patent expiry but is likely to spur efforts to develop biosimilars. » Más en wiwo.de